Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

Fig. 1

Worst left ventricular ejection fraction (LVEF) for each year of treatment. N is the number of patients with an LVEF assessment on study within the year on H. In cases of multiple LVEF assessments per patient within the same year, the lowest value is reported. Abbreviations: H trastuzumab (Herceptin®), LVEF left ventricular ejection fraction

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us